Liver Diseases  >>  sovaprevir (ACH 1625)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
sovaprevir (ACH 1625) / AstraZeneca
NCT01180790 / 2010-022092-65: Safety, Tolerability, and Antiviral Activity of ACH-0141625 or Placebo in Combination With Peginterferon and Ribavirin in Hepatitis C Virus (HCV) Positive Participants

Completed
2a
122
Europe, US
ACH-0141625 (Sovaprevir), Placebo, Pegylated Interferon alpha-2a, Peg-INF, Ribavirin, Ribasphere, Copegus
Alexion, Achillion, a wholly owned subsidiary of Alexion
Hepatitis C
03/12
04/13
NCT01849562: Safety, Tolerability, and Efficacy of 12-weeks of Sovaprevir, ACH-3102, and Ribavirin in Treatment-naive GT-1 HCV Participants

Checkmark Highlights of Clinical Results
Feb 2015 - Feb 2015: Highlights of Clinical Results
Checkmark For ACH-3102 + RBV Phase 2a-005 trial for hep C infection
Jun 2014 - Jun 2014: For ACH-3102 + RBV Phase 2a-005 trial for hep C infection
Checkmark ACH-3102 + sovaprevir + RBV trial for hep C infection
More
Completed
2a
30
NA
Sovaprevir, ACH-0141625, ACH-3102, Ribavirin, Placebo
Alexion, Achillion, a wholly owned subsidiary of Alexion
Hepatitis C, Chronic
11/13
04/14

Download Options